Abstract
Background
Women with a history of breast cancer (BC) more commonly have a diagnosis of other primary malignancies (OPMs) than the general population. This study sought to evaluate OPMs among patients with BC who underwent germline testing with a hereditary BC gene panel.
Methods
The study identified women 18 years of age or older with a history of unilateral BC who underwent multi-gene panel testing between January 2014 and August 2019 at the authors’ institution. Patient, tumor, and treatment factors for BC and OPM diagnoses were collected for descriptive, univariate, and overall survival (OS) analyses.
Results
Among 1163 patients, 330 (28.4%) had an OPM. The median follow-up period was 4.1 years from BC diagnosis. Of the 1163 patients, 209 (18%) had a BRCA pathogenic variant (PV), 306 (26.4%) had a non-BRCA PV, and 648 (55.7%) had no PV. Development of an OPM varied according to germline testing result, with an OPM developing for 18.6% (39/209) of the patients with a BRCA PV, 31.8% (204/648) of the patients with no PV, and 28.4% (87/306) of the patients with a non-BRCA PV (p < 0.0001). The most common OPMs were ovarian (n = 60), uterine (n = 44), sarcoma (n = 36), melanoma (n = 27), colorectal (n = 22), and lymphoma (n = 20) malignancies. The 5-year OS was 96%. The patients with an OPM 5 years after BC diagnosis had a shorter OS than those who did not (93.4% vs 97.5%; p = 0.002).
Conclusion
More than 25% of women with BC who underwent germline panel testing had an OPM diagnosed during the short-term follow-up period, and the diagnosis of an OPM was associated with reduced OS. These data have implications for counseling BC patients who undergo germline testing regarding future cancer screening.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Yi M, Cormier JN, Xing Y, et al. Other primary malignancies in breast cancer patients treated with breast-conserving surgery and radiation therapy. Ann Surg Oncol. 2013;20:1514–21.
National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2022. Retrieved 22 September 2021 at https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.
Bazire L, De Rycke Y, Asselain B, et al. Risks of second malignancies after breast cancer treatment: long-term results. Cancer Radiother. 2017;21:10–5.
Brown LM, Chen BE, Pfeiffer RM, et al. Risk of second non-hematological malignancies among 376,825 breast cancer survivors. Breast Cancer Res Treat. 2007;106:439–51.
Fowble B, Hanlon A, Freedman G, et al. Second cancers after conservative surgery and radiation for stages I-II breast cancer: identifying a subset of women at increased risk. Int J Radiat Oncol Biol Phys. 2001;51:679–90.
Galper S, Gelman R, Recht A, et al. Second nonbreast malignancies after conservative surgery and radiation therapy for early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:406–14.
Kirova YM, De Rycke Y, Gambotti L, et al. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 2008;98:870–4.
Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285–92.
Heymann S, Delaloge S, Rahal A, et al. Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol. 2010;5:104.
Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer. 2016;122:3673–81.
Petry V, Bonadio RC, Cagnacci AQC, et al. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome). Fam Cancer. 2020;19(1):47–53.
Rubino C, Shamsaldin A, Le MG, et al. Radiation dose and risk of soft tissue and bone sarcoma after breast cancer treatment. Breast Cancer Res Treat. 2005;89:277–88.
Salminen SH, Sampo MM, Bohling TO, et al. Radiation-associated sarcoma after breast cancer in a nationwide population: increasing risk of angiosarcoma. Cancer Med. 2018;7:4825–35.
Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231–7.
Schlosser S, Rabinovitch R, Shatz Z, et al. Radiation-associated secondary malignancies in BRCA mutation carriers treated for breast cancer. Int J Radiat Oncol Biol Phys. 2020;107:353–9.
Sanchez L, Lana A, Hidalgo A, et al. Risk factors for second primary tumours in breast cancer survivors. Eur J Cancer Prev. 2008;17:406–13.
Acknowledgments
The research reported in this article was supported by the NCI of the NIH under award P30CA016672 to the University of Texas MD Anderson Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosure
Dr. Kelly Hunt is on the Medical Advisory Board of Armanda Health and AstraZeneca and receives research funding to the University of Texas MD Anderson Cancer Center from Cairn Surgical, Eli Lilly and Co, and Lumicell. The remaining authors have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Murphy, B.L., Yi, M., Gutierrez Barrera, A.M. et al. Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing. Ann Surg Oncol 30, 1663–1668 (2023). https://doi.org/10.1245/s10434-022-12468-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-12468-2